Advanced Technology Ventures

Actifio, Inc. is a provider of copy data virtualization solutions, headquartered in Waltham, Massachusetts, with a global presence including locations in India, Australia, New Zealand, Germany, Japan, China, Singapore, and the United Kingdom. Founded in 2009, the company specializes in Enterprise Data-as-a-Service, offering a suite of products designed to help organizations manage their data more efficiently. Key offerings include Actifio CDS, which supports large-scale deployments in diverse data center environments, and Actifio Sky, a platform tailored for distributed enterprises. Additionally, Actifio provides Big Data Director for protecting extensive file systems and Actifio Resiliency Director for automated recovery solutions. The company also features cloud-based services such as Actifio One for managed services and OnVault for long-term data retention and analytics. By utilizing its Virtual Data Pipeline technology, Actifio enables businesses to decouple data from infrastructure, enhancing resiliency, agility, and access to cloud resources while optimizing data management costs.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

Gynesonics, Inc. is a medical device company focused on developing innovative solutions for women's health, specifically addressing symptomatic uterine fibroids. Founded in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, Gynesonics offers the Sonata System, a minimally invasive treatment that utilizes sonography guidance for the transcervical ablation of fibroids. This incision-free approach provides a safe and effective alternative to traditional surgical methods such as hysterectomy or myomectomy, aiming to alleviate severe menstrual symptoms associated with fibroids. Gynesonics is dedicated to improving the quality of care for women by offering advanced technologies that enhance treatment options in gynecology.

Oasys Water, Inc. is a Boston-based company that specializes in forward osmosis technology aimed at addressing the global water crisis. Founded in 2008, the company has developed Engineered Osmosis, a proprietary platform that enhances the efficiency of desalination processes, making the treatment of saltwater more economical. Oasys Water's integrated systems focus on high recovery desalination, brine management, and zero liquid discharge solutions. By utilizing advanced resource recovery techniques, the company significantly lowers the cost of producing clean water and energy, enabling industries to optimize resource use while minimizing environmental impact. Oasys Water also maintains an office in Dubai to support its international operations.

Cedexis Inc. is a company that specializes in Internet performance control and monitoring solutions. Founded in 2009 by veterans of the web hosting and content delivery market, Cedexis provides a suite of tools designed to optimize web performance across various data centers, delivery networks, and clouds. Its flagship products include Cedexis Radar, a traffic management platform; Cedexis Openmix, a data-driven cloud routing platform that directs traffic based on real-time performance data; and Cedexis Pulse, which allows users to access application-specific information. The company offers adaptive automation to optimize traffic dynamically, ensuring that businesses can select the best-performing clouds for their needs. Cedexis is particularly valuable for media, retail, and consumer brands that depend on high availability and fast load times to enhance user experience and drive revenue. Headquartered in Portland, Oregon, Cedexis also has offices in Paris, San Francisco, and sales representatives across multiple countries including the United Kingdom and Germany.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

Gynesonics, Inc. is a medical device company focused on developing innovative solutions for women's health, specifically addressing symptomatic uterine fibroids. Founded in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, Gynesonics offers the Sonata System, a minimally invasive treatment that utilizes sonography guidance for the transcervical ablation of fibroids. This incision-free approach provides a safe and effective alternative to traditional surgical methods such as hysterectomy or myomectomy, aiming to alleviate severe menstrual symptoms associated with fibroids. Gynesonics is dedicated to improving the quality of care for women by offering advanced technologies that enhance treatment options in gynecology.

Thrasos is a bio-therapeutics company dedicated to discovering and developing targeted therapies for severe organ failure, with a primary emphasis on kidney diseases. The company's lead program, THR-184, aims to prevent and treat acute kidney injury (AKI). Additionally, Thrasos is advancing a preclinical development program that addresses chronic kidney disease (CKD). The company also focuses on developing innovative treatments for rare kidney-related conditions, such as myeloma cast nephropathy, which occurs when protein aggregates obstruct renal tubules, leading to the risk of permanent kidney damage. Through its efforts, Thrasos seeks to provide timely and effective treatment options for patients suffering from these serious kidney issues.

Planful, Inc. is a financial planning and analysis platform that provides cloud-based enterprise performance management software. Its solutions facilitate financial planning, consolidation, reporting, and analytics, with features that support cash flow forecasting, annual operating planning, workforce planning, and monthly financial closing. The platform aims to streamline processes, enhance collaboration, and improve workflow efficiency for organizations across various industries, including education, energy, food, insurance, life sciences, manufacturing, non-profit, retail, and transportation. Planful enables users to reduce manual efforts, accelerate cycle times, and enhance the accuracy of financial reporting. Founded in 2007 and headquartered in Redwood City, California, with additional offices in Scottsdale, Arizona, and Hyderabad, India, Planful was previously known as Host Analytics, Inc. The company serves over 1,000 clients globally, including well-known brands such as the Boston Red Sox and 23andMe.

Valeritas Holdings, Inc. was a medical technology company focused on developing and commercializing innovative solutions for the treatment of Type 2 diabetes. Founded in 2006 and headquartered in Bridgewater, New Jersey, the company offered the V-Go, a wearable insulin delivery device designed for basal-bolus therapy, allowing patients to manage their insulin intake conveniently and discreetly. Valeritas was also working on additional products, including the V-Go Prefill, aimed at simplifying the device-filling process, and V-Go SIM, which would facilitate real-time tracking of dosing utilization. The company marketed its products through third-party wholesalers and medical supply distributors, aiming to enhance the health and quality of life for individuals living with diabetes. However, on June 30, 2020, Valeritas Holdings filed for Chapter 11 bankruptcy, leading to its cessation of operations.

Gynesonics, Inc. is a medical device company focused on developing innovative solutions for women's health, specifically addressing symptomatic uterine fibroids. Founded in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, Gynesonics offers the Sonata System, a minimally invasive treatment that utilizes sonography guidance for the transcervical ablation of fibroids. This incision-free approach provides a safe and effective alternative to traditional surgical methods such as hysterectomy or myomectomy, aiming to alleviate severe menstrual symptoms associated with fibroids. Gynesonics is dedicated to improving the quality of care for women by offering advanced technologies that enhance treatment options in gynecology.

Evergage, Inc. is a technology company that specializes in a cloud-based real-time personalization platform aimed at enhancing customer engagement for digital marketers. Founded in 2010 and based in Somerville, Massachusetts, Evergage offers a suite of solutions that enable marketers to create individualized experiences for website visitors and mobile app users. Key offerings include the Evergage Platform, which allows for website personalization; Evergage Recommend, which provides tailored product and content recommendations; and Evergage Promote, which catalogs and promotes assets based on user behavior. The platform also includes tools for tracking shopping patterns, analyzing user history through engagement algorithms, and delivering customized experiences based on visitor data. Evergage serves various industries, including retail, financial services, technology, and hospitality, and has facilitated personalized interactions for over 2 billion web visitors across more than 150 organizations. The company has received multiple awards for its innovative approach to digital marketing.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

Nuvaira, Inc. is a medical device company based in Minneapolis, Minnesota, focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). Founded in 2008, Nuvaira specializes in a novel catheter-based Lung Denervation System that aims to address airway nerve hyperactivity by targeting the parasympathetic innervation of the lungs. This minimally invasive procedure is designed to improve lung function, enhance exercise capacity, and elevate the quality of life for patients suffering from chronic respiratory conditions. With a commitment to advancing treatment options, Nuvaira seeks to reduce the clinical consequences associated with neural hyperactivity in conditions such as COPD and asthma.

Actifio, Inc. is a provider of copy data virtualization solutions, headquartered in Waltham, Massachusetts, with a global presence including locations in India, Australia, New Zealand, Germany, Japan, China, Singapore, and the United Kingdom. Founded in 2009, the company specializes in Enterprise Data-as-a-Service, offering a suite of products designed to help organizations manage their data more efficiently. Key offerings include Actifio CDS, which supports large-scale deployments in diverse data center environments, and Actifio Sky, a platform tailored for distributed enterprises. Additionally, Actifio provides Big Data Director for protecting extensive file systems and Actifio Resiliency Director for automated recovery solutions. The company also features cloud-based services such as Actifio One for managed services and OnVault for long-term data retention and analytics. By utilizing its Virtual Data Pipeline technology, Actifio enables businesses to decouple data from infrastructure, enhancing resiliency, agility, and access to cloud resources while optimizing data management costs.

PowerVision, Inc. is a medical device company based in Belmont, California, focused on developing advanced intraocular lenses (IOLs) designed to restore vision for individuals affected by presbyopia and cataracts. Established in 2002, the company has created the FluidVision accommodating intraocular lens technology, which simulates the natural function of a healthy eye. This innovative lens utilizes a small amount of fluid to adjust its shape dynamically, allowing for clear vision at various distances. PowerVision aims to address the vision challenges faced by millions, particularly the over 20 million individuals in the U.S. with cataracts and the more than 90 million affected by presbyopia. The FluidVision lens represents a significant advancement in vision correction, potentially freeing patients from the need for glasses or other vision correction methods. In 2019, PowerVision was acquired by Alcon Laboratories, Inc.

Aquion Energy specializes in developing and commercializing innovative energy storage solutions, particularly its proprietary Aqueous Hybrid Ion (AHI™) batteries. These sodium ion batteries are designed for stationary energy storage and are notable for their environmentally friendly design, utilizing non-toxic components such as saltwater. Aquion's technology addresses the limitations of traditional energy storage systems, providing safe, reliable, and sustainable options that are non-flammable and non-explosive. By enhancing the electrical grid, Aquion's AHI systems optimize existing generation assets and facilitate the broader adoption of renewable energy technologies, thereby contributing to the reduction of reliance on fossil fuels.

Aquion Energy specializes in developing and commercializing innovative energy storage solutions, particularly its proprietary Aqueous Hybrid Ion (AHI™) batteries. These sodium ion batteries are designed for stationary energy storage and are notable for their environmentally friendly design, utilizing non-toxic components such as saltwater. Aquion's technology addresses the limitations of traditional energy storage systems, providing safe, reliable, and sustainable options that are non-flammable and non-explosive. By enhancing the electrical grid, Aquion's AHI systems optimize existing generation assets and facilitate the broader adoption of renewable energy technologies, thereby contributing to the reduction of reliance on fossil fuels.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for patients affected by rare allergic and immunological diseases. The company focuses on creating life-changing treatments, with its lead program, STAR-0215, being a monoclonal antibody designed to inhibit plasma kallikrein, currently in preclinical development for hereditary angioedema. Additionally, Astria is advancing STAR-0310, another monoclonal antibody, which targets the OX40 receptor and is also in preclinical development for atopic dermatitis, a condition characterized by impaired skin barrier function and significant itching. Through its targeted approach, Astria Therapeutics aims to address unmet medical needs in the field of immunology.

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule drugs targeting tumor metabolism and immunology for cancer treatment. Headquartered in South San Francisco, California, the company’s lead product candidate, CB-839, is an inhibitor of glutaminase currently in Phase II clinical trials for solid tumors. Additionally, Calithera is developing INCB001158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology, as well as CB-280, another oral arginase inhibitor aimed at treating cystic fibrosis, and CB-708, an orally administered small molecule inhibitor of CD73. The company has established collaborations with Bristol-Myers Squibb to evaluate the combination of nivolumab with CB-839, and with Incyte Corporation for the development and commercialization of INCB001158. Founded in 2010, Calithera Biosciences is dedicated to advancing innovative therapies that specifically target critical pathways in tumor growth and survival.

Fuze Digital Solutions, LLC is a provider of a cloud-based unified communications platform that enhances productivity and collaboration within enterprises. The platform, known as Fuze Suite, offers various features including business voice communications, video conferencing, and a suite of tools for customer care and engagement. These tools encompass a community knowledge base, case management, chat, feedback management, and online reporting, all designed to foster customer loyalty through effective communication. Founded in 2002 and originally known as ThinkingPhones, Fuze serves a diverse clientele, including organizations like Careerbuilder.com and Oregon Health & Sciences University. The company is headquartered in Boston, Massachusetts, with additional offices in major cities across North America and Europe, positioning itself as a key player in the unified communications market.

Coskata, Inc. is a renewable energy company focused on producing liquid fuels through innovative biological processes. The company specializes in the development of technologies for converting various input materials, including natural gas, wood, and industrial waste, into cellulosic ethanol. Utilizing proprietary microorganisms and advanced bioreactor designs, Coskata aims to deliver solutions that enhance economic viability, environmental sustainability, and national security. Its capabilities in molecular biology and process engineering enable the effective transformation of diverse resources into valuable fuels and chemicals, positioning Coskata as a leader in the renewable energy sector.

Rive Technology is a clean energy company focused on the commercialization of advanced catalyst technology for petroleum refining. The company has developed proprietary technology, originally invented at MIT, that enhances traditional zeolite catalysts by introducing novel medium pore size channels. This innovation allows for greater accessibility of large hydrocarbon molecules, significantly increasing the yield of transportation fuels such as gasoline and diesel from each barrel of crude oil. Rive's catalysts are designed to integrate seamlessly into existing refinery operations, enabling refiners to boost throughput and profitability with minimal capital investment. By improving process efficiency and product yields, Rive's technology offers a compelling solution for the petroleum refining industry.

Solar Junction is a manufacturer of high efficiency III-V multi-junction solar cells based on ASLAM ™ materials. The company is dedicated to providing the industry’s highest efficiency solar cells to enable CPV as a cost effective energy solution. Founded in 2007, Solar Junction is headquartered in San Jose, California. Investors include New Enterprise Associates, Draper Fisher Jurvetson and Advanced Technology Ventures.

Planful, Inc. is a financial planning and analysis platform that provides cloud-based enterprise performance management software. Its solutions facilitate financial planning, consolidation, reporting, and analytics, with features that support cash flow forecasting, annual operating planning, workforce planning, and monthly financial closing. The platform aims to streamline processes, enhance collaboration, and improve workflow efficiency for organizations across various industries, including education, energy, food, insurance, life sciences, manufacturing, non-profit, retail, and transportation. Planful enables users to reduce manual efforts, accelerate cycle times, and enhance the accuracy of financial reporting. Founded in 2007 and headquartered in Redwood City, California, with additional offices in Scottsdale, Arizona, and Hyderabad, India, Planful was previously known as Host Analytics, Inc. The company serves over 1,000 clients globally, including well-known brands such as the Boston Red Sox and 23andMe.

Gynesonics, Inc. is a medical device company focused on developing innovative solutions for women's health, specifically addressing symptomatic uterine fibroids. Founded in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, Gynesonics offers the Sonata System, a minimally invasive treatment that utilizes sonography guidance for the transcervical ablation of fibroids. This incision-free approach provides a safe and effective alternative to traditional surgical methods such as hysterectomy or myomectomy, aiming to alleviate severe menstrual symptoms associated with fibroids. Gynesonics is dedicated to improving the quality of care for women by offering advanced technologies that enhance treatment options in gynecology.

Nuvaira, Inc. is a medical device company based in Minneapolis, Minnesota, focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). Founded in 2008, Nuvaira specializes in a novel catheter-based Lung Denervation System that aims to address airway nerve hyperactivity by targeting the parasympathetic innervation of the lungs. This minimally invasive procedure is designed to improve lung function, enhance exercise capacity, and elevate the quality of life for patients suffering from chronic respiratory conditions. With a commitment to advancing treatment options, Nuvaira seeks to reduce the clinical consequences associated with neural hyperactivity in conditions such as COPD and asthma.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for patients affected by rare allergic and immunological diseases. The company focuses on creating life-changing treatments, with its lead program, STAR-0215, being a monoclonal antibody designed to inhibit plasma kallikrein, currently in preclinical development for hereditary angioedema. Additionally, Astria is advancing STAR-0310, another monoclonal antibody, which targets the OX40 receptor and is also in preclinical development for atopic dermatitis, a condition characterized by impaired skin barrier function and significant itching. Through its targeted approach, Astria Therapeutics aims to address unmet medical needs in the field of immunology.

Planful, Inc. is a financial planning and analysis platform that provides cloud-based enterprise performance management software. Its solutions facilitate financial planning, consolidation, reporting, and analytics, with features that support cash flow forecasting, annual operating planning, workforce planning, and monthly financial closing. The platform aims to streamline processes, enhance collaboration, and improve workflow efficiency for organizations across various industries, including education, energy, food, insurance, life sciences, manufacturing, non-profit, retail, and transportation. Planful enables users to reduce manual efforts, accelerate cycle times, and enhance the accuracy of financial reporting. Founded in 2007 and headquartered in Redwood City, California, with additional offices in Scottsdale, Arizona, and Hyderabad, India, Planful was previously known as Host Analytics, Inc. The company serves over 1,000 clients globally, including well-known brands such as the Boston Red Sox and 23andMe.

GluMetrics, Inc. is a medical device company based in Irvine, California, founded in 2005. It specializes in developing innovative tools for clinicians to enhance the care of critically ill patients, particularly through continuous glucose monitoring. The company's primary product, GluCath, is an intravascular device designed to provide real-time blood glucose measurements for hospitalized patients, facilitating better management of their glucose levels. By focusing on continuous monitoring, GluMetrics aims to improve patient outcomes in critical care settings.

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule drugs targeting tumor metabolism and immunology for cancer treatment. Headquartered in South San Francisco, California, the company’s lead product candidate, CB-839, is an inhibitor of glutaminase currently in Phase II clinical trials for solid tumors. Additionally, Calithera is developing INCB001158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology, as well as CB-280, another oral arginase inhibitor aimed at treating cystic fibrosis, and CB-708, an orally administered small molecule inhibitor of CD73. The company has established collaborations with Bristol-Myers Squibb to evaluate the combination of nivolumab with CB-839, and with Incyte Corporation for the development and commercialization of INCB001158. Founded in 2010, Calithera Biosciences is dedicated to advancing innovative therapies that specifically target critical pathways in tumor growth and survival.

Modria, Inc. is a developer of a cloud-based online dispute resolution platform that automates the process of resolving customer disputes related to eCommerce. Established in 2011 and headquartered in San Jose, California, with an additional office in Chennai, India, Modria serves a diverse clientele that includes tangible goods and service marketplaces, payment networks, medium and large online merchants, government agencies, and classified sites. The platform seamlessly integrates with the back-end architecture and front-end user experience of eCommerce sites, allowing businesses to efficiently resolve customer issues without human intervention. As of May 30, 2017, Modria operates as a subsidiary of Tyler Technologies, Inc.

Thrasos is a bio-therapeutics company dedicated to discovering and developing targeted therapies for severe organ failure, with a primary emphasis on kidney diseases. The company's lead program, THR-184, aims to prevent and treat acute kidney injury (AKI). Additionally, Thrasos is advancing a preclinical development program that addresses chronic kidney disease (CKD). The company also focuses on developing innovative treatments for rare kidney-related conditions, such as myeloma cast nephropathy, which occurs when protein aggregates obstruct renal tubules, leading to the risk of permanent kidney damage. Through its efforts, Thrasos seeks to provide timely and effective treatment options for patients suffering from these serious kidney issues.

Fuze Digital Solutions, LLC is a provider of a cloud-based unified communications platform that enhances productivity and collaboration within enterprises. The platform, known as Fuze Suite, offers various features including business voice communications, video conferencing, and a suite of tools for customer care and engagement. These tools encompass a community knowledge base, case management, chat, feedback management, and online reporting, all designed to foster customer loyalty through effective communication. Founded in 2002 and originally known as ThinkingPhones, Fuze serves a diverse clientele, including organizations like Careerbuilder.com and Oregon Health & Sciences University. The company is headquartered in Boston, Massachusetts, with additional offices in major cities across North America and Europe, positioning itself as a key player in the unified communications market.

Nuvaira, Inc. is a medical device company based in Minneapolis, Minnesota, focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). Founded in 2008, Nuvaira specializes in a novel catheter-based Lung Denervation System that aims to address airway nerve hyperactivity by targeting the parasympathetic innervation of the lungs. This minimally invasive procedure is designed to improve lung function, enhance exercise capacity, and elevate the quality of life for patients suffering from chronic respiratory conditions. With a commitment to advancing treatment options, Nuvaira seeks to reduce the clinical consequences associated with neural hyperactivity in conditions such as COPD and asthma.

QuickPay was founded in 2010 with a vision to leverage trends in mobile technology to remove the pain and hassle of finding, accessing, and paying for parking and transportation. Their revolutionary QP QuickPay mobile parking platform offers users one mobile parking application that works across all parking environments — drivers can even raise parking gates using their mobile phones — and gives parking owners and operators an efficient way to enable mobile parking across all their assets with a single integrated solution. Today drivers can use QP QuickPay and a mobile phone to find and pay for parking at hundreds of locations across the U.S., with new locations being added continually.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

Evergage, Inc. is a technology company that specializes in a cloud-based real-time personalization platform aimed at enhancing customer engagement for digital marketers. Founded in 2010 and based in Somerville, Massachusetts, Evergage offers a suite of solutions that enable marketers to create individualized experiences for website visitors and mobile app users. Key offerings include the Evergage Platform, which allows for website personalization; Evergage Recommend, which provides tailored product and content recommendations; and Evergage Promote, which catalogs and promotes assets based on user behavior. The platform also includes tools for tracking shopping patterns, analyzing user history through engagement algorithms, and delivering customized experiences based on visitor data. Evergage serves various industries, including retail, financial services, technology, and hospitality, and has facilitated personalized interactions for over 2 billion web visitors across more than 150 organizations. The company has received multiple awards for its innovative approach to digital marketing.

EndPlay is a prominent provider of cloud-based software solutions focused on content management, engagement, and monetization. Utilizing its proprietary 'Intelligent Rendering' technology, EndPlay offers a comprehensive platform that enables clients to efficiently create, manage, and deliver content optimized for a variety of devices. The company's architecture is designed for extensibility and integrates seamlessly with various partners, allowing clients to effectively navigate the challenges of Big Data and dynamic content environments. EndPlay serves a diverse range of enterprise clients across sectors such as media, entertainment, consumer packaged goods, and education, offering robust support through its experienced Client Services team. This team assists with collaboration, implementation, and optimization of EndPlay solutions, ensuring high levels of customer satisfaction. In addition to its innovative offerings, EndPlay provides training and support services, including certification programs that enhance platform productivity. Headquartered in Los Angeles, EndPlay is expanding its presence with regional offices in Florida and New Jersey, and is also looking to grow in European and Asian markets.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

GluMetrics, Inc. is a medical device company based in Irvine, California, founded in 2005. It specializes in developing innovative tools for clinicians to enhance the care of critically ill patients, particularly through continuous glucose monitoring. The company's primary product, GluCath, is an intravascular device designed to provide real-time blood glucose measurements for hospitalized patients, facilitating better management of their glucose levels. By focusing on continuous monitoring, GluMetrics aims to improve patient outcomes in critical care settings.

Solar Junction is a manufacturer of high efficiency III-V multi-junction solar cells based on ASLAM ™ materials. The company is dedicated to providing the industry’s highest efficiency solar cells to enable CPV as a cost effective energy solution. Founded in 2007, Solar Junction is headquartered in San Jose, California. Investors include New Enterprise Associates, Draper Fisher Jurvetson and Advanced Technology Ventures.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for patients affected by rare allergic and immunological diseases. The company focuses on creating life-changing treatments, with its lead program, STAR-0215, being a monoclonal antibody designed to inhibit plasma kallikrein, currently in preclinical development for hereditary angioedema. Additionally, Astria is advancing STAR-0310, another monoclonal antibody, which targets the OX40 receptor and is also in preclinical development for atopic dermatitis, a condition characterized by impaired skin barrier function and significant itching. Through its targeted approach, Astria Therapeutics aims to address unmet medical needs in the field of immunology.

Actifio, Inc. is a provider of copy data virtualization solutions, headquartered in Waltham, Massachusetts, with a global presence including locations in India, Australia, New Zealand, Germany, Japan, China, Singapore, and the United Kingdom. Founded in 2009, the company specializes in Enterprise Data-as-a-Service, offering a suite of products designed to help organizations manage their data more efficiently. Key offerings include Actifio CDS, which supports large-scale deployments in diverse data center environments, and Actifio Sky, a platform tailored for distributed enterprises. Additionally, Actifio provides Big Data Director for protecting extensive file systems and Actifio Resiliency Director for automated recovery solutions. The company also features cloud-based services such as Actifio One for managed services and OnVault for long-term data retention and analytics. By utilizing its Virtual Data Pipeline technology, Actifio enables businesses to decouple data from infrastructure, enhancing resiliency, agility, and access to cloud resources while optimizing data management costs.

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule drugs targeting tumor metabolism and immunology for cancer treatment. Headquartered in South San Francisco, California, the company’s lead product candidate, CB-839, is an inhibitor of glutaminase currently in Phase II clinical trials for solid tumors. Additionally, Calithera is developing INCB001158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology, as well as CB-280, another oral arginase inhibitor aimed at treating cystic fibrosis, and CB-708, an orally administered small molecule inhibitor of CD73. The company has established collaborations with Bristol-Myers Squibb to evaluate the combination of nivolumab with CB-839, and with Incyte Corporation for the development and commercialization of INCB001158. Founded in 2010, Calithera Biosciences is dedicated to advancing innovative therapies that specifically target critical pathways in tumor growth and survival.

Valeritas Holdings, Inc. was a medical technology company focused on developing and commercializing innovative solutions for the treatment of Type 2 diabetes. Founded in 2006 and headquartered in Bridgewater, New Jersey, the company offered the V-Go, a wearable insulin delivery device designed for basal-bolus therapy, allowing patients to manage their insulin intake conveniently and discreetly. Valeritas was also working on additional products, including the V-Go Prefill, aimed at simplifying the device-filling process, and V-Go SIM, which would facilitate real-time tracking of dosing utilization. The company marketed its products through third-party wholesalers and medical supply distributors, aiming to enhance the health and quality of life for individuals living with diabetes. However, on June 30, 2020, Valeritas Holdings filed for Chapter 11 bankruptcy, leading to its cessation of operations.

Aquion Energy specializes in developing and commercializing innovative energy storage solutions, particularly its proprietary Aqueous Hybrid Ion (AHI™) batteries. These sodium ion batteries are designed for stationary energy storage and are notable for their environmentally friendly design, utilizing non-toxic components such as saltwater. Aquion's technology addresses the limitations of traditional energy storage systems, providing safe, reliable, and sustainable options that are non-flammable and non-explosive. By enhancing the electrical grid, Aquion's AHI systems optimize existing generation assets and facilitate the broader adoption of renewable energy technologies, thereby contributing to the reduction of reliance on fossil fuels.

Cedexis Inc. is a company that specializes in Internet performance control and monitoring solutions. Founded in 2009 by veterans of the web hosting and content delivery market, Cedexis provides a suite of tools designed to optimize web performance across various data centers, delivery networks, and clouds. Its flagship products include Cedexis Radar, a traffic management platform; Cedexis Openmix, a data-driven cloud routing platform that directs traffic based on real-time performance data; and Cedexis Pulse, which allows users to access application-specific information. The company offers adaptive automation to optimize traffic dynamically, ensuring that businesses can select the best-performing clouds for their needs. Cedexis is particularly valuable for media, retail, and consumer brands that depend on high availability and fast load times to enhance user experience and drive revenue. Headquartered in Portland, Oregon, Cedexis also has offices in Paris, San Francisco, and sales representatives across multiple countries including the United Kingdom and Germany.

PowerVision, Inc. is a medical device company based in Belmont, California, focused on developing advanced intraocular lenses (IOLs) designed to restore vision for individuals affected by presbyopia and cataracts. Established in 2002, the company has created the FluidVision accommodating intraocular lens technology, which simulates the natural function of a healthy eye. This innovative lens utilizes a small amount of fluid to adjust its shape dynamically, allowing for clear vision at various distances. PowerVision aims to address the vision challenges faced by millions, particularly the over 20 million individuals in the U.S. with cataracts and the more than 90 million affected by presbyopia. The FluidVision lens represents a significant advancement in vision correction, potentially freeing patients from the need for glasses or other vision correction methods. In 2019, PowerVision was acquired by Alcon Laboratories, Inc.

Verastem, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments aimed at improving the survival and quality of life for cancer patients. Based in Needham, Massachusetts, Verastem markets COPIKTRA (duvelisib), an oral medication indicated for adult patients with relapsed or refractory chronic lymphocytic leukemia and follicular lymphoma after multiple prior therapies. In addition to this approved therapy, the company is advancing its pipeline with the focal adhesion kinase inhibitor defactinib, which is being studied in combination with immunotherapies for various cancers, including pancreatic and ovarian cancers, as well as non-small cell lung cancer. Verastem's research emphasizes inhibiting critical signaling pathways that promote cancer cell survival and tumor growth, particularly those associated with the RAS/MAPK pathway. The company has formed collaborative agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited to enhance its development efforts. Founded in 2010, Verastem continues to focus on late-stage development of its anticancer agents.

Evergage, Inc. is a technology company that specializes in a cloud-based real-time personalization platform aimed at enhancing customer engagement for digital marketers. Founded in 2010 and based in Somerville, Massachusetts, Evergage offers a suite of solutions that enable marketers to create individualized experiences for website visitors and mobile app users. Key offerings include the Evergage Platform, which allows for website personalization; Evergage Recommend, which provides tailored product and content recommendations; and Evergage Promote, which catalogs and promotes assets based on user behavior. The platform also includes tools for tracking shopping patterns, analyzing user history through engagement algorithms, and delivering customized experiences based on visitor data. Evergage serves various industries, including retail, financial services, technology, and hospitality, and has facilitated personalized interactions for over 2 billion web visitors across more than 150 organizations. The company has received multiple awards for its innovative approach to digital marketing.

PolyRemedy offers integrated wound management systems designed to increase consistency by extending wound care expertise to the point of care. The PolyRemedy Personalized Woundcare System (PWS) enables clinicians to document care through easy-to-use, web-based assessment tools and order personalized wound dressings, while also providing critical and unprecedented visibility into wound care data. It was founded in 2004 and is headquartered in Concord, Massachusetts.

[x+1] is a recognized leader in marketing technology, specifically noted for its advanced capabilities in both data management and demand-side platform services. The company offers the Origin Platform, a comprehensive programmatic marketing hub that enables brands to engage effectively with their audiences through various digital channels. Utilizing its Origin Data Management Platform, which combines first and third-party data with a Predictive Optimization Engine, [x+1] facilitates targeted audience engagement across online display, mobile, email, and other digital mediums. This capability has made [x+1] a trusted partner for many top brands, particularly in the financial services sector. Headquartered in New York City, [x+1] also has offices in Connecticut, Illinois, Michigan, and California.

Rive Technology is a clean energy company focused on the commercialization of advanced catalyst technology for petroleum refining. The company has developed proprietary technology, originally invented at MIT, that enhances traditional zeolite catalysts by introducing novel medium pore size channels. This innovation allows for greater accessibility of large hydrocarbon molecules, significantly increasing the yield of transportation fuels such as gasoline and diesel from each barrel of crude oil. Rive's catalysts are designed to integrate seamlessly into existing refinery operations, enabling refiners to boost throughput and profitability with minimal capital investment. By improving process efficiency and product yields, Rive's technology offers a compelling solution for the petroleum refining industry.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for patients affected by rare allergic and immunological diseases. The company focuses on creating life-changing treatments, with its lead program, STAR-0215, being a monoclonal antibody designed to inhibit plasma kallikrein, currently in preclinical development for hereditary angioedema. Additionally, Astria is advancing STAR-0310, another monoclonal antibody, which targets the OX40 receptor and is also in preclinical development for atopic dermatitis, a condition characterized by impaired skin barrier function and significant itching. Through its targeted approach, Astria Therapeutics aims to address unmet medical needs in the field of immunology.

Actifio, Inc. is a provider of copy data virtualization solutions, headquartered in Waltham, Massachusetts, with a global presence including locations in India, Australia, New Zealand, Germany, Japan, China, Singapore, and the United Kingdom. Founded in 2009, the company specializes in Enterprise Data-as-a-Service, offering a suite of products designed to help organizations manage their data more efficiently. Key offerings include Actifio CDS, which supports large-scale deployments in diverse data center environments, and Actifio Sky, a platform tailored for distributed enterprises. Additionally, Actifio provides Big Data Director for protecting extensive file systems and Actifio Resiliency Director for automated recovery solutions. The company also features cloud-based services such as Actifio One for managed services and OnVault for long-term data retention and analytics. By utilizing its Virtual Data Pipeline technology, Actifio enables businesses to decouple data from infrastructure, enhancing resiliency, agility, and access to cloud resources while optimizing data management costs.

Qumu Corporation specializes in providing comprehensive tools for enterprises to create, manage, secure, distribute, and measure live and on-demand video content. The company offers an end-to-end solution that includes software licenses, server appliances, software-enabled devices, and a cloud-hosted software-as-a-service platform. In addition to these products, Qumu provides maintenance, support, and professional services. Its solutions cater to a variety of sectors, including banking, finance, insurance, manufacturing, telecom, technology, and healthcare, as well as government entities, through both direct sales and partnerships. Founded in 1978 and headquartered in Minneapolis, Minnesota, Qumu was formerly known as Rimage Corporation before rebranding in 2013. The majority of the company's revenue is generated from North America, with additional markets in Europe and Asia.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

NeuroVista Corporation is a medical device company based in Seattle, Washington, focused on developing innovative technologies for the management and treatment of epilepsy in the United States. Founded in 2002 and originally known as BioNeuronics Corporation until its rebranding in 2007, NeuroVista aims to address the challenges faced by the approximately 3 million Americans living with epilepsy, a neurological condition characterized by unpredictable seizures. These seizures can vary significantly in severity and impact daily life, affecting individuals primarily between the ages of 15 and 64. Through its advisory technologies, NeuroVista seeks to provide tools that help mitigate the uncertainty surrounding the timing of epileptic seizures, ultimately improving the quality of life for those affected by this condition.

Calxeda provides revolutionary efficiency to the data center. Leveraging ultra-low power technology from ARM, servers built on Calxeda’s silicon and software platform consume a fraction of the power and space of today’s best-in-class servers, enabling data centers to realize significant reduction in capital and operating expenses. The Calxeda platform scales efficiently to thousands of server nodes, with unique network and storage acceleration, and is enhanced with management technology to deliver true “energy-proportional” computing. The result is a stunning breakthrough in performance efficiency, density, and scalability.

Coskata, Inc. is a renewable energy company focused on producing liquid fuels through innovative biological processes. The company specializes in the development of technologies for converting various input materials, including natural gas, wood, and industrial waste, into cellulosic ethanol. Utilizing proprietary microorganisms and advanced bioreactor designs, Coskata aims to deliver solutions that enhance economic viability, environmental sustainability, and national security. Its capabilities in molecular biology and process engineering enable the effective transformation of diverse resources into valuable fuels and chemicals, positioning Coskata as a leader in the renewable energy sector.

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule drugs targeting tumor metabolism and immunology for cancer treatment. Headquartered in South San Francisco, California, the company’s lead product candidate, CB-839, is an inhibitor of glutaminase currently in Phase II clinical trials for solid tumors. Additionally, Calithera is developing INCB001158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology, as well as CB-280, another oral arginase inhibitor aimed at treating cystic fibrosis, and CB-708, an orally administered small molecule inhibitor of CD73. The company has established collaborations with Bristol-Myers Squibb to evaluate the combination of nivolumab with CB-839, and with Incyte Corporation for the development and commercialization of INCB001158. Founded in 2010, Calithera Biosciences is dedicated to advancing innovative therapies that specifically target critical pathways in tumor growth and survival.

Acceleron Pharma is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2003. It specializes in discovering, developing, and commercializing therapeutics to treat serious and rare diseases. Acceleron's portfolio includes luspatercept-aamt, marketed as REBLOZYL for treating anemia in adult patients with beta-thalassemia, and also under investigation for myelodysplastic syndromes and myelofibrosis. Additionally, the company is developing Sotatercept for pulmonary arterial hypertension and ACE-083 for Charcot-Marie-Tooth disease. Acceleron's research focuses on growth and differentiation factors that regulate cellular proliferation, differentiation, and survival in various tissue types. The company collaborates with other organizations to advance its therapeutic candidates.

Planful, Inc. is a financial planning and analysis platform that provides cloud-based enterprise performance management software. Its solutions facilitate financial planning, consolidation, reporting, and analytics, with features that support cash flow forecasting, annual operating planning, workforce planning, and monthly financial closing. The platform aims to streamline processes, enhance collaboration, and improve workflow efficiency for organizations across various industries, including education, energy, food, insurance, life sciences, manufacturing, non-profit, retail, and transportation. Planful enables users to reduce manual efforts, accelerate cycle times, and enhance the accuracy of financial reporting. Founded in 2007 and headquartered in Redwood City, California, with additional offices in Scottsdale, Arizona, and Hyderabad, India, Planful was previously known as Host Analytics, Inc. The company serves over 1,000 clients globally, including well-known brands such as the Boston Red Sox and 23andMe.

Zeltiq Aesthetics, Inc. is a medical technology company founded in 2005 and headquartered in Pleasanton, California. It specializes in the development and commercialization of non-invasive products aimed at the selective reduction of fat. The company's flagship product, the CoolSculpting system, employs a patented method known as Cryolipolysis, which utilizes precisely controlled cooling to target and eliminate stubborn fat cells without damaging surrounding tissue. This FDA-cleared device is designed for various applications in dermatologic treatments and is marketed primarily to dermatologists, plastic surgeons, and aesthetic specialists across North America, the Asia-Pacific, Europe, and Latin America. Zeltiq Aesthetics was formerly known as Juniper Medical, Inc. and rebranded in July 2007. As of 2017, it operates as a subsidiary of Allergan plc.

Altura Medical, Inc. is a medical device company based in Menlo Park, California, focused on developing innovative endograft technology for the treatment of abdominal aortic aneurysms (AAA) and associated conditions. The company's flagship product, the Agili-D AAA System, represents a next-generation endovascular aneurysm repair solution designed to improve patient outcomes. Founded in 2008, Altura Medical has built a reputation for its differentiated technology, which is supported by a skilled management team and a network of prominent venture capital investors. As of 2015, Altura Medical operates as a subsidiary of Lombard Medical, Inc.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for patients affected by rare allergic and immunological diseases. The company focuses on creating life-changing treatments, with its lead program, STAR-0215, being a monoclonal antibody designed to inhibit plasma kallikrein, currently in preclinical development for hereditary angioedema. Additionally, Astria is advancing STAR-0310, another monoclonal antibody, which targets the OX40 receptor and is also in preclinical development for atopic dermatitis, a condition characterized by impaired skin barrier function and significant itching. Through its targeted approach, Astria Therapeutics aims to address unmet medical needs in the field of immunology.

Solar Junction is a manufacturer of high efficiency III-V multi-junction solar cells based on ASLAM ™ materials. The company is dedicated to providing the industry’s highest efficiency solar cells to enable CPV as a cost effective energy solution. Founded in 2007, Solar Junction is headquartered in San Jose, California. Investors include New Enterprise Associates, Draper Fisher Jurvetson and Advanced Technology Ventures.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

Silicor Materials, Inc. specializes in the production of solar silicon for photovoltaic cell and module manufacturers globally. Established in 2006 and headquartered in San Jose, California, the company operates manufacturing facilities in Vaughan, Canada, and Mississippi, along with a research and development center in Berlin, Germany. Silicor Materials offers high-quality, low-cost solar silicon, which serves as an alternative to more expensive electronic-grade silicon, thereby enabling photovoltaic module manufacturers to lower their production costs while adhering to demanding performance standards. In addition to solar silicon, the company produces aluminum by-products, including aluminum-silicon master alloys and polyaluminum chloride, which are utilized in municipal and industrial water treatment applications.

Planful, Inc. is a financial planning and analysis platform that provides cloud-based enterprise performance management software. Its solutions facilitate financial planning, consolidation, reporting, and analytics, with features that support cash flow forecasting, annual operating planning, workforce planning, and monthly financial closing. The platform aims to streamline processes, enhance collaboration, and improve workflow efficiency for organizations across various industries, including education, energy, food, insurance, life sciences, manufacturing, non-profit, retail, and transportation. Planful enables users to reduce manual efforts, accelerate cycle times, and enhance the accuracy of financial reporting. Founded in 2007 and headquartered in Redwood City, California, with additional offices in Scottsdale, Arizona, and Hyderabad, India, Planful was previously known as Host Analytics, Inc. The company serves over 1,000 clients globally, including well-known brands such as the Boston Red Sox and 23andMe.

Nuventix is a thermal management solutions provider based in Austin, Texas. The company specializes in the development of the SynJet module, a patented synthetic jet cooling technology that effectively removes heat using turbulent pulses of air generated by an electromagnetic actuator. Initially successful in computer cooling applications, Nuventix has expanded its innovative technology to the LED market, significantly advancing it beyond conventional timelines. This development enables more efficient general illumination designs that leverage the advantages of LED technology, thereby influencing industry standards and practices.

Ardian is a privately held, clinical-stage medical device company that develops catheter-based therapies for hypertension treatment and related conditions. It develops a catheter system that uses radio-frequency energy to “deactivate” sympathetic nerves in the kidneys, lowering blood pressure. The company's flagship product, the Symplicity Catheter System, addresses uncontrolled hypertension through renal denervation, or ablation of the nerves lining the renal arteries. It has received the CE (Conformité Européene) mark and Australia's Therapeutic Goods Administration (TGA) listing but is not yet approved by the U.S. Food and Drug Administration (FDA).

GI Dynamics, Inc. is a medical device company that specializes in designing, developing, and manufacturing non-surgical therapies for the treatment of type 2 diabetes and obesity. The company’s primary product, EndoBarrier, is aimed at helping patients manage their condition and reduce obesity without the need for surgical intervention. GI Dynamics serves healthcare providers and third-party distributors, selling its products mainly in Europe, the Middle East, the Asia Pacific, and South America. Founded in 2003, the company is headquartered in Lexington, Massachusetts.

Oasys Water, Inc. is a Boston-based company that specializes in forward osmosis technology aimed at addressing the global water crisis. Founded in 2008, the company has developed Engineered Osmosis, a proprietary platform that enhances the efficiency of desalination processes, making the treatment of saltwater more economical. Oasys Water's integrated systems focus on high recovery desalination, brine management, and zero liquid discharge solutions. By utilizing advanced resource recovery techniques, the company significantly lowers the cost of producing clean water and energy, enabling industries to optimize resource use while minimizing environmental impact. Oasys Water also maintains an office in Dubai to support its international operations.

Hydra Biosciences, headquartered in Cambridge, Massachusetts, is a biopharmaceutical company dedicated to developing innovative drugs targeting pain, inflammation, and cardiovascular diseases. The company leverages its expertise in novel ion channels and proprietary high-throughput screening platforms to identify and advance drug candidates addressing substantial unmet medical needs. Hydra's focus lies in TRP ion channels, offering potential for selective and safer therapies compared to classical voltage-gated channels. Since its founding, Hydra has secured significant funding from prominent investors such as Abingworth Ventures, Advanced Technology Ventures, and New Enterprise Associates, among others.

CombineNet, Inc. is a technology company specializing in advanced sourcing solutions for a diverse range of organizations, including mid-sized and global companies across various industries. With over a decade of experience, CombineNet provides its clients with the tools needed to make informed supplier and spend decisions. Its flagship product, the Advanced Sourcing Application Platform (ASAP), is a web-based software-as-a-service solution designed to streamline the creation, launch, and management of sourcing events, regardless of size or complexity. The platform focuses on optimizing sourcing processes and improving decision-making for complex spend categories, thereby enhancing overall procurement efficiency.

Coskata, Inc. is a renewable energy company focused on producing liquid fuels through innovative biological processes. The company specializes in the development of technologies for converting various input materials, including natural gas, wood, and industrial waste, into cellulosic ethanol. Utilizing proprietary microorganisms and advanced bioreactor designs, Coskata aims to deliver solutions that enhance economic viability, environmental sustainability, and national security. Its capabilities in molecular biology and process engineering enable the effective transformation of diverse resources into valuable fuels and chemicals, positioning Coskata as a leader in the renewable energy sector.

Silicor Materials, Inc. specializes in the production of solar silicon for photovoltaic cell and module manufacturers globally. Established in 2006 and headquartered in San Jose, California, the company operates manufacturing facilities in Vaughan, Canada, and Mississippi, along with a research and development center in Berlin, Germany. Silicor Materials offers high-quality, low-cost solar silicon, which serves as an alternative to more expensive electronic-grade silicon, thereby enabling photovoltaic module manufacturers to lower their production costs while adhering to demanding performance standards. In addition to solar silicon, the company produces aluminum by-products, including aluminum-silicon master alloys and polyaluminum chloride, which are utilized in municipal and industrial water treatment applications.

Anagran specializes in flow-based traffic management products designed to mitigate the adverse effects of network congestion, thereby facilitating the seamless scaling of video, voice, data, and wireless traffic across converged IP networks. The company's solutions protect essential network traffic by managing end-to-end flows based on their behavior, ensuring optimal quality and performance levels without relying on invasive deep packet inspection techniques. This approach allows service providers and enterprises to consistently achieve high-performance standards while significantly lowering both capital expenditures and ongoing network costs. Founded by Dr. Larry Roberts, a recognized pioneer of the Internet, Anagran is committed to enhancing network efficiency and reliability.

Valeritas Holdings, Inc. was a medical technology company focused on developing and commercializing innovative solutions for the treatment of Type 2 diabetes. Founded in 2006 and headquartered in Bridgewater, New Jersey, the company offered the V-Go, a wearable insulin delivery device designed for basal-bolus therapy, allowing patients to manage their insulin intake conveniently and discreetly. Valeritas was also working on additional products, including the V-Go Prefill, aimed at simplifying the device-filling process, and V-Go SIM, which would facilitate real-time tracking of dosing utilization. The company marketed its products through third-party wholesalers and medical supply distributors, aiming to enhance the health and quality of life for individuals living with diabetes. However, on June 30, 2020, Valeritas Holdings filed for Chapter 11 bankruptcy, leading to its cessation of operations.

Proteolix is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies aimed at targeting protein degradation pathways to treat cancer and autoimmune diseases. The company’s lead product is a highly specific proteasome inhibitor, which represents a novel class of therapeutics being evaluated for safety and efficacy in multiple myeloma and other malignancies. In addition to this, Proteolix is developing a diverse pipeline of proteasome inhibitors, including both an oral formulation and a selective immunoproteasome inhibitor. These advancements aim to provide healthcare professionals with effective treatments for various hematologic cancers, thereby improving patient outcomes.

ChannelAdvisor is a provider of cloud-based multichannel commerce solutions aimed at enhancing the e-commerce operations of brands and retailers. The company's platform facilitates the management of various sales channels, enabling users to streamline processes such as inventory availability and pricing optimization. By offering data analytics capabilities, ChannelAdvisor empowers its clients to improve their online performance and competitiveness. The company is dedicated to helping businesses expand their reach, connect with consumers throughout the buying cycle, and ultimately drive sales growth from a centralized platform.

GluMetrics, Inc. is a medical device company based in Irvine, California, founded in 2005. It specializes in developing innovative tools for clinicians to enhance the care of critically ill patients, particularly through continuous glucose monitoring. The company's primary product, GluCath, is an intravascular device designed to provide real-time blood glucose measurements for hospitalized patients, facilitating better management of their glucose levels. By focusing on continuous monitoring, GluMetrics aims to improve patient outcomes in critical care settings.

AltaRock Energy, Inc., established in 2007, is a geothermal energy technology and services company. Headquartered in Seattle, Washington, with additional offices in Sausalito, California, AltaRock specializes in the development and commercialization of geothermal technology to produce clean, renewable power. The company offers a range of services, including project development, management, operations, performance improvement, and reservoir maintenance for both new and existing geothermal projects. AltaRock is also involved in greenfield enhanced geothermal systems projects and commercial stimulation services, aiming to expand the capacity of existing geothermal resources and increase profitability. The company's leadership includes Don O'Shei, Chief Executive Officer, and Susan Petty, President and Chief Technology Officer.

Qumu Corporation specializes in providing comprehensive tools for enterprises to create, manage, secure, distribute, and measure live and on-demand video content. The company offers an end-to-end solution that includes software licenses, server appliances, software-enabled devices, and a cloud-hosted software-as-a-service platform. In addition to these products, Qumu provides maintenance, support, and professional services. Its solutions cater to a variety of sectors, including banking, finance, insurance, manufacturing, telecom, technology, and healthcare, as well as government entities, through both direct sales and partnerships. Founded in 1978 and headquartered in Minneapolis, Minnesota, Qumu was formerly known as Rimage Corporation before rebranding in 2013. The majority of the company's revenue is generated from North America, with additional markets in Europe and Asia.

Rive Technology is a clean energy company focused on the commercialization of advanced catalyst technology for petroleum refining. The company has developed proprietary technology, originally invented at MIT, that enhances traditional zeolite catalysts by introducing novel medium pore size channels. This innovation allows for greater accessibility of large hydrocarbon molecules, significantly increasing the yield of transportation fuels such as gasoline and diesel from each barrel of crude oil. Rive's catalysts are designed to integrate seamlessly into existing refinery operations, enabling refiners to boost throughput and profitability with minimal capital investment. By improving process efficiency and product yields, Rive's technology offers a compelling solution for the petroleum refining industry.

Wakonda Technologies was founded in 2005 by Dr. Les Fritzemeier and Professor Ryne Raffaelle of the Rochester Institute of Technology. The company was established to exploit the intersection of their respective skills in metallurgical processing and advanced photovoltaic devices. Wakonda was started in Rochester NY and used the facilities at RIT, Cornell University and several government agencies to conduct proof of concept experiments. In 2008, the company moved to Massachusetts to accelerate product development and early commercialization. Wakonda has received several honors over its short history, winning the first ever Golden Horseshoe Business Challenge in upstate NY and being named the National Renewable Energy Laboratory's Entrepreneur of the Year in 2007.

[x+1] is a recognized leader in marketing technology, specifically noted for its advanced capabilities in both data management and demand-side platform services. The company offers the Origin Platform, a comprehensive programmatic marketing hub that enables brands to engage effectively with their audiences through various digital channels. Utilizing its Origin Data Management Platform, which combines first and third-party data with a Predictive Optimization Engine, [x+1] facilitates targeted audience engagement across online display, mobile, email, and other digital mediums. This capability has made [x+1] a trusted partner for many top brands, particularly in the financial services sector. Headquartered in New York City, [x+1] also has offices in Connecticut, Illinois, Michigan, and California.

Solar Junction is a manufacturer of high efficiency III-V multi-junction solar cells based on ASLAM ™ materials. The company is dedicated to providing the industry’s highest efficiency solar cells to enable CPV as a cost effective energy solution. Founded in 2007, Solar Junction is headquartered in San Jose, California. Investors include New Enterprise Associates, Draper Fisher Jurvetson and Advanced Technology Ventures.

Cenzic is a company that specializes in application security testing for enterprise software, particularly within the Software as a Service sector. It offers a comprehensive range of security testing solutions tailored for mobile, web, and cloud applications. Cenzic's approach goes beyond traditional signature-based tools, focusing on the automatic identification of application vulnerabilities. In addition to its testing services, the company provides security training, including penetration testing training and professional implementation training. Cenzic also offers consulting services in software engineering, available both on-site and remotely, to enhance the security posture of its clients' applications.

Handango is a global provider of smartphone applications, offering over 140,000 titles across BlackBerry, Palm, Windows Mobile, Symbian OS, and Linux platforms. With a network of 23,000 content partners and extensive distribution channels, Handango delivers top-selling apps such as games, business tools, entertainment software, and productivity solutions to millions of consumers worldwide. Users can access these applications via the company's website, partner sites, SD cards, or directly from their smartphones using Handango's proprietary InHand platform. The company has collaborated with prominent industry partners like Microsoft, Verizon Wireless, T-Mobile, AT&T, LG, Samsung, Best Buy, and CNET to expand its reach and service offerings.

Hydra Biosciences, headquartered in Cambridge, Massachusetts, is a biopharmaceutical company dedicated to developing innovative drugs targeting pain, inflammation, and cardiovascular diseases. The company leverages its expertise in novel ion channels and proprietary high-throughput screening platforms to identify and advance drug candidates addressing substantial unmet medical needs. Hydra's focus lies in TRP ion channels, offering potential for selective and safer therapies compared to classical voltage-gated channels. Since its founding, Hydra has secured significant funding from prominent investors such as Abingworth Ventures, Advanced Technology Ventures, and New Enterprise Associates, among others.

Aperio Technologies is a prominent provider of digital pathology solutions, serving hospitals, reference laboratories, and pharmaceutical and research institutions globally. The company offers a comprehensive product portfolio designed to enhance patient care through improved quality assurance and more efficient workflows. Its offerings include ScanScope scanners, Spectrum image management software, the SecondSlide slide sharing service, and various image analysis tools and services. Aperio's products are FDA cleared for specific clinical applications and are also intended for research and educational purposes in other areas. By focusing on accessibility and educational support for pathologists, Aperio aims to facilitate access to new and targeted therapies while enhancing the overall quality of pathology services.

Coskata, Inc. is a renewable energy company focused on producing liquid fuels through innovative biological processes. The company specializes in the development of technologies for converting various input materials, including natural gas, wood, and industrial waste, into cellulosic ethanol. Utilizing proprietary microorganisms and advanced bioreactor designs, Coskata aims to deliver solutions that enhance economic viability, environmental sustainability, and national security. Its capabilities in molecular biology and process engineering enable the effective transformation of diverse resources into valuable fuels and chemicals, positioning Coskata as a leader in the renewable energy sector.

PolyRemedy offers integrated wound management systems designed to increase consistency by extending wound care expertise to the point of care. The PolyRemedy Personalized Woundcare System (PWS) enables clinicians to document care through easy-to-use, web-based assessment tools and order personalized wound dressings, while also providing critical and unprecedented visibility into wound care data. It was founded in 2004 and is headquartered in Concord, Massachusetts.